pocketful logo
Sandu Pharmaceuticals Ltd logo

Sandu Pharmaceuticals Ltd

NSE: BSE: 524703

35

(-1.07%)

Tue, 10 Mar 2026, 09:30 pm

Sandu Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    32.75

  • Net Profit

    1.55

  • P/B

    1.41

  • Sector P/E

    32.42

  • P/E

    30.43

  • EV/EBITDA

    15.24

  • Debt/Equity (Industry)

    0.26

  • Interest Cover (Industry)

    10.89

  • ROCE (Industry)

    16.43

  • RONW (Industry)

    14.36

  • ROE

    4.74

  • ROCE

    6.87

  • Debt/Equity

    0

  • EPS (TTM)

    1.61

  • Dividend Yield

    2.36

  • Book Value

    34.63

  • Interest Cover

    22.60

Analysis

all

thumbs up icon

Pros

  • Sandu Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sandu Pharmaceuticals is profitable, therefore cash runway is not a concern.
  • Sandu Pharmaceuticals is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (123.2%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 6.1x debt.
thumbs up icon

Cons

  • Unable to evaluate Sandu Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sandu Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • High level of physical assets or inventory.
  • Umesh's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Sandu Pharmaceuticals is not covered by any analysts.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters37.7942.9042.9042.9042.90
FII00000
DII0.010.010.010.010.01
Public62.2157.0957.0957.0957.09
Government00000

Read More

Technical Analysis

RSI

48.06

MACD

-0.29

50 DMA

35.94

200 DMA

43.92

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic54.9045.7640.3836.6231.2427.4818.34
Fibonacci45.7642.2740.1136.6233.1330.9727.48
Camarilla37.5136.6835.8436.6234.1633.3232.49

Pivots Level: Classic

R3

+18.28

54.90

R2

+9.14

45.76

R1

+3.76

40.38

36.62
36.62
Pivot Point
LTP: 35

S1

-5.38

31.24

S2

-9.14

27.48

S3

-18.28

18.34

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    34.95

  • 20-EMA

    35.16

  • 30-EMA

    35.41

  • 50-EMA

    36.19

  • 100-EMA

    38.57

  • 200-EMA

    42.61

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
06 Feb 2026board-meetingsQuarterly Results
18 Aug 2025dividendFinal Dividend - Rs. - 0.818 Sept 2025
13 Aug 2025agm
28 May 2025dividend₹0.80 Dividend /Share18 Sept 2025
12 Aug 2024agm
12 Aug 2024dividend₹0.80 Dividend /Share20 Sept 2024
12 Aug 2023dividend₹0.75 Dividend /Share19 Sept 2023
12 Aug 2023agm
12 Aug 2022agm
12 Aug 2022dividend₹0.75 Dividend /Share23 Sept 2022

Read More

Peer Comparison

Sandu Pharmaceuticals Ltd logo

Sandu Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Sandu Pharmaceuticals Ltd About

Sandu Pharmaceuticals is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU. e company has its manufacturing plant in Goa.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1985

Headquarters

CEO

Balaram Vishwanathan

Employees

Contact

Website icon

Website

http://www.sandu.in

Email icon

Email

corp.sec@sandu.in

Phone icon

Phone

Location icon

Location

Plot No 25/26/29 & 30, Pilerne Indl Estate Marra Bard, Bardez, Goa, 403511

Read More

Sandu Pharmaceuticals Ltd Company History

YearHistory
1899
  • Sandu Brothers started the manufacture of Ayurvedic medicines on 10th May.
2000
  • Sandu earned ISO 9001:2000 certification for its Group operations.
2024

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
TRANS SCAN SECURITIES PVT LTDBuy10600055.8819 Mar 2024
DPS TRADELINK PRIVATE LIMITEDSell10406155.8519 Mar 2024
PORINJU VELIYATHSell4350051.9909 Jul 2021
AMI STOCK SHARE BROKERS PLTDSell450017.8820 Mar 2009
REENA JASVANTBHAI JANIBuy450007.7520 Mar 2009
RAMESH G GOKANIBuy450007.8517 Mar 2009
AMI STOCK SHARE BROKERS PLTDBuy450007.9509 Feb 2009
RAMESH G GOKANISell450007.9509 Feb 2009
RAMESH G GOKANIBuy450008.430 Jan 2009
AMI STOCK SHARE BROKERS PLTDSell450008.430 Jan 2009

Read More

Sandu Pharmaceuticals Ltd News

Sandu Pharma Reports No Fund Deviation in Q3 FY26

Sandu Pharmaceuticals Limited filed its quarterly statement confirming no deviation in utilization of funds raised through preferential issue across three tranches for Q3 FY26 ended December 31, 2025.

06 Feb 2026

co actions results

Sandu Pharmaceuticals Q3FY26 Results Show Growth

Sandu Pharmaceuticals reported Q3FY26 net profit of ₹97.51 lakhs, up from ₹55.55 lakhs in Q3FY25. Revenue reached ₹1876.09 lakhs with nine-month profit at ₹172.27 lakhs.

06 Feb 2026

co actions results

Sandu Pharmaceuticals Board Meet on Feb 6, 2026

Sandu Pharmaceuticals Limited has scheduled a board meeting on February 06, 2026, to approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025.

24 Jan 2026

co actions results

Sandu Pharma Gets GST Notice for ₹13L Discrepancy

Sandu Pharmaceuticals receives GST notice from Maharashtra authorities regarding ₹13.00 lakh discrepancy in ITC reversal for FY2023-24. Company expects favorable outcome.

22 Dec 2025

stocks

Sandu Pharmaceuticals Shareholders Approve Reclassification of Akshath Finvest from Promoter to Public Category

Sandu Pharmaceuticals Limited received shareholder approval through postal ballot to reclassify Akshath Finvest and Properties Private Limited from promoter/promoter group to public category, involving 4,94,182 shares representing 5.12% shareholding. The resolution was passed with 92.02% votes in favor, reducing promoter shareholding from 42.90% to 37.79% and increasing public shareholding from 57.10% to 62.21%.

19 Nov 2025

corporate action

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800